Advances on vasculogenic mimicry in breast cancer

doi:10.3969/j.issn.1674-490X.2022.02.003

Abstract

Abstract: Vasculogenic mimicry is a special model of angiogenesis. This structure is composed of tumor cells instead of traditional endothelial cells, and provides nutrition for tumor growth, invasion and metastasis. In recent years, it has been found that vasculogenic mimicry is related to the prognosis, invasion, metastasis and drug resistance of many kinds of malignant tumors. It is generally believed that vasculogenic mimicry and angiogenesis depend on some common mechanisms. And some people believe that the formation of vasculogenic mimicry is one of the reasons leading to the development of resistance to anti-angiogenic drugs. The mechanism of vasculogenic mimicry in breast cancer, including related signaling pathways, as well as tumor stem cells, epithelial mesenchymal and anti angiogenesis therapy, are reviewed. The significance and future direction of vasculogenic mimicry as a therapeutic target for breast cancer will be prospected.

Key words: vasculogenic mimicry, breast cancer, cancer stem cells, epithelial-mesenchymal transition, antiangiogenic therapy

CLC Number:

WEI Yali,SUN Chengcheng,WANG Xiaochun. Advances on vasculogenic mimicry in breast cancer[J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(2): 16-23.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249.DOI: 10.3322/caac.21660.
[2] BIANCHINI G, BALKO J M, MAYER I A, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11): 674-690. DOI: 10.1038/nrclinonc.2016.66.
[3] GEYER F C, PAREJA F, WEIGELT B, et al. The spectrum of triple-negative breast disease: high- and low-grade lesions[J]. Am J Pathol, 2017,187(10): 2139-2151. DOI: 10.1016/j.ajpath.2017.03.016.
[4] FOLKMAN J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186. DOI: 10.1056/NEJM197111182852108.
[5] JIANG X J, WANG J, DENG X Y, et al. The role of microenvironment in tumor angiogenesis[J].J Exp Clin Cancer Res, 2020, 39(1): 204. DOI: 10.1186/s13046-020-01709-5.
[6] WEI F, WANG D, WEI J Y, et al. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance[J].Cell Mol Life Sci, 2021, 78(1): 173-193. DOI: 10.1007/s00018-020-03581-0.
[7] VIALLARD C, LARRIVÉE B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets[J]. Angiogenesis, 2017, 20(4): 409-426. DOI: 10.1007/s10456-017-9562-9.
[8] YURA Y, CHONG B S H, JOHNSON R D, et al. Endothelial cell-specific redox gene modulation inhibits angiogenesis but promotes B16F0 tumor growth in mice[J]. FASEB J, 2019, 33(12): 14147-14158. DOI: 10.1096/fj.201900786R.
[9] MANIOTIS A J, FOLBERG R, HESS A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol, 1999, 155(3): 739-752. DOI: 10.1016/S0002-9440(10)65173-5.
[10] IZAWA Y, KASHII-MAGARIBUCHI K, YOSHIDA K, et al. Stem-like human breast cancer cells initiate vasculogenic mimicry on matrigel[J]. Acta Histochem Cytochem, 2018, 51(6): 173-183. DOI: 10.1267/ahc.18041.
[11] SUN W, FAN Y Z, ZHANG W Z, et al. A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro[J]. J Exp Clin Cancer Res, 2011, 30(1): 46. DOI: 10.1186/1756-9966-30-46.
[12] MILLIMAGGI D, MARI M, ASCENZO S D, et al. Vasculogenic mimicry of human ovarian cancer cells: role of CD147[J]. Int J Oncol, 2009, 35(6): 1423-1428. DOI: 10.3892/ijo_00000460.
[13] YUE W Y, CHEN Z P. Does vasculogenic mimicry exist in astrocytoma? [J]. J Histochem Cytochem, 2005, 53(8): 997-1002. DOI: 10.1369/jhc.4A6521.2005.
[14] CAI X S, JIA Y W, MEI J, et al. Tumor blood vessels formation in osteosarcoma: vasculogenesis mimicry[J]. Chin Med J(Engl), 2004, 117(1): 94-98.
[15] VARTANIAN A A. Signaling pathways in tumor vasculogenic mimicry[J]. Biochemistry(Mosc), 2012, 77(9): 1044-1055. DOI: 10.1134/S000629791209012X.
[16] LIU X, WANG J H, LI S, et al. Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase/ERK-MMP-laminin5γ2 signaling pathway[J]. Cancer Sci, 2015, 106(7): 857-866. DOI: 10.1111/cas.12684.
[17] ANDONEGUI-ELGUERA M A, ALFARO-MORA Y, CÁCERES-GUTIÉRREZ R, et al. An overview of vasculogenic mimicry in breast cancer[J]. Front Oncol, 2020, 10: 220. DOI: 10.3389/fonc.2020.00220.
[18] VANNINI I, FANINI F, FABBRI M. Emerging roles of microRNAs in cancer[J]. Curr Opin Genet Dev, 2018, 48: 128-133. DOI: 10.1016/j.gde.2018.01.001.
[19] LI G X, HUANG M, CAI Y Q, et al. miR-141 inhibits glioma vasculogenic mimicry by controlling EphA2 expression[J]. Mol Med Rep, 2018, 18(2): 1395-1404. DOI: 10.3892/mmr.2018.9108.
[20] LIM D, CHO J G, YUN E, et al. MicroRNA 34a-AXL axis regulates vasculogenic mimicry formation in breast cancer cells[J]. Genes, 2020, 12(1): 9. DOI: 10.3390/genes12010009.
[21] AN G L, LU F, HUANG S K, et al. Effects of miR 93 on epithelial to mesenchymal transition and vasculogenic mimicry in triple negative breast cancer cells[J]. Molecular Medicine Reports, 2021, 23(1): 30. DOI: 10.3892/mmr.2020.11668.
[22] YI M, TAN Y X, WANG L, et al. TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development[J]. Cell Mol Life Sci, 2020, 77(21): 4325-4346. DOI: 10.1007/s00018-020-03539-2.
[23] RISAU W. Mechanisms of angiogenesis[J]. Nature, 1997, 386(6626): 671-674. DOI: 10.1038/386671a0.
[24] PRAGER B C, XIE Q, BAO S D, et al. Cancer stem cells: the architects of the tumor ecosystem[J]. Cell Stem Cell, 2019, 24(1): 41-53. DOI: 10.1016/j.stem.2018.12.009.
[25] SUN H Z, YAO N, CHENG S Q, et al. Cancer stem-like cells directly participate in vasculogenic mimicry channels in triple-negative breast cancer[J]. Cancer Biol Med, 2019, 16(2): 299-311. DOI: 10.20892/j.issn.2095-3941.2018.0209.
[26] LIU T J, SUN B C, ZHAO X L, et al. CD133⁺ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer[J]. Oncogene, 2013, 32(5): 544-553. DOI: 10.1038/onc.2012.85.
[27] GONG W C, SUN B C, SUN H Z, et al. Nodal signaling activates the Smad2/3 pathway to regulate stem cell-like properties in breast cancer cells[J].Am J Cancer Res, 2017, 7(3): 503-517.
[28] GONG W C, SUN B C, ZHAO X L, et al. Nodal signaling promotes vasculogenic mimicry formation in breast cancer via the Smad2/3 pathway[J]. Oncotarget, 2016, 7(43): 70152-70167. DOI: 10.18632/oncotarget.12161.
[29] HILL B S, SARNELLA A, D’AVINO G, et al. Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer[J]. Semin Cancer Biol, 2020, 60: 202-213. DOI: 10.1016/j.semcancer.2019.07.028.
[30] INOUE T, UMEZAWA A, TAKENAKA T, et al. The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models[J]. Kidney Int, 2015, 87(1): 233-238. DOI: 10.1038/ki.2014.235.
[31] PONNUSAMY M P, SESHACHARYULU P, LAKSHMANAN I, et al. Emerging role of mucins in epithelial to mesenchymal transition[J]. Curr Cancer Drug Targets, 2013, 13(9): 945-956. DOI: 10.2174/15680096113136660100.
[32] LIU T J, ZHAO X L, ZHENG X, et al. The EMT transcription factor, Twist1, as a novel therapeutic target for pulmonary sarcomatoid carcinomas[J]. Int J Oncol, 2020, 56(3): 750-760. DOI: 10.3892/ijo.2020.4972.
[33] ZHANG Y, WEINBERG R A. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities[J]. Front Med, 2018, 12(4): 361-373. DOI: 10.1007/s11684-018-0656-6.
[34] CELIÉ-TERRASSA T, JOLLY M K. Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis[J]. Cold Spring Harb Perspect Med, 2020, 10(7): a036905. DOI: 10.1101/cshperspect.a036905.
[35] SHIBUE T, WEINBERG R A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications[J]. Nat Rev Clin Oncol, 2017, 14(10): 611-629. DOI: 10.1038/nrclinonc.2017.44.
[36] O'CONOR C J, CHEN T, GONZÁLEZ I, et al. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker[J]. Biomark Med, 2018, 12(7): 813-820. DOI: 10.2217/bmm-2017-0398.
[37] MITRA D, BHATTACHARYYA S, ALAM N, et al. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast[J]. Breast Cancer Res Treat, 2020, 179(2): 359-370. DOI: 10.1007/s10549-019-05482-8.
[38] BRANTLEY-SIEDERS D M, JIANG A X, SARMA K, et al. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome[J]. PLoS One, 2011, 6(9): e24426. DOI: 10.1371/journal.pone.0024426.
[39] LABELLE M, SCHNITTLER H J, AUST D E, et al. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling[J]. Cancer Res, 2008, 68(5): 1388-1397. DOI: 10.1158/0008-5472.CAN-07-2706.
[40] NIE C Y, LV H F, BIE L Y, et al. Hypoxia-inducible factor 1-alpha expression correlates with response to neoadjuvant chemotherapy in women with breast cancer[J]. Medicine, 2018, 97(51): e13551. DOI: 10.1097/MD.0000000000013551.
[41] REZAEI M, CAO J H, FRIEDRICH K, et al. The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor-endothelial cell interactions[J]. Histochem Cell Biol, 2018, 149(1): 15-30. DOI: 10.1007/s00418-017-1619-8.
[42] JU R J, LI X T, SHI J F, et al. Liposomes, modified with PTD(HIV-1)peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer[J]. Biomaterials, 2014, 35(26): 7610-7621. DOI: 10.1016/j.biomaterials.2014.05.040.
[43] ZENG F, JU R J, LIU L, et al. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer[J]. Oncotarget, 2015, 6(34): 36625-36642. DOI: 10.18632/oncotarget.5382.
[44] LI S X, ZHANG Q Y, ZHOU L C, et al. Inhibitory effects of compound DMBT on hypoxia-induced vasculogenic mimicry in human breast cancer[J]. Biomed Pharmacother, 2017, 96: 982-992. DOI: 10.1016/j.biopha.2017.11.137.
[45] XU M R, WEI P F, SUO M Z, et al. Brucine suppresses vasculogenic mimicry in human triple-negative breast cancer cell line MDA-MB-231[J]. Biomed Res Int, 2019, 2019: 6543230. DOI: 10.1155/2019/6543230.
[46] MAHFOUZ N, TAHTOUH R, ALAAEDDINE N, et al. Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF1α and VEGF receptors[J]. PLoS One, 2017, 12(6): e0179202. DOI: 10.1371/journal.pone.0179202.
[47] ZARRIN B, ZARIFI F, VASEGHI G, et al. Acquired tumor resistance to antiangiogenic therapy: mechanisms at a glance[J]. J Res Med Sci, 2017, 22: 117. DOI: 10.4103/jrms.JRMS_182_17.
[48] XIE W, ZHAO H J, WANG F X, et al. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway[J]. J Exp Clin Cancer Res, 2021, 40(1): 30. DOI: 10.1186/s13046-020-01800-x.
[49] HSIEH M J, LIN C W, SU S C, et al. Effects of miR-34b/miR-892a upregulation and inhibition of ABCB1/ABCB4 on melatonin-induced apoptosis in VCR-resistant oral cancer cells[J]. Mol Ther Nucleic Acids, 2020, 19: 877-889. DOI: 10.1016/j.omtn.2019.12.022.
[50] CHENG J, YANG H L, GU C J, et al. Melatonin restricts the viability and angiogenesis of vascular endothelial cells by suppressing HIF1α/ROS/VEGF[J]. Int J Mol Med, 2019, 43(2): 945-955. DOI: 10.3892/ijmm.2018.4021.
[51] MAROUFI N F, AMIRI M, DIZAJI B F, et al. Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition(EMT)in breast cancer stem cells[J]. Eur J Pharmacol, 2020, 881: 173282. DOI: 10.1016/j.ejphar.2020.173282.